The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease.

The latest data suggests that, in patients with type 2 diabetes and chronic kidney disease, Ozempic slashes the risk of kidney failure, substantial loss of kidney function, or death from kidney ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide ... disease in adults with type 2 diabetes and chronic kidney disease. The Danish drugmaker said the approval ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

Discover expert tips from an obesity medicine doctor on effective and sustainable ways to approach weight loss for type 2 ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand access soon.

Dr Sof Andrikopoulos explains why moderation is key to prevention—and how new therapies are changing the game in diabetes ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists ...